Tranexamic Technologies designates a group of affiliated companies managed by two medical industry entrepreneurs with deep experience in new product identification and development. We have assembled a team of experts from academia, clinical practice, private labs, and professional organizations to develop very broad new therapies based on the intersection of certain fundamental biological activities and previously unexamined mechanisms of action of a new class of drugs that we have named the Tranexamic Class Antagonists (TXCAs) of positively charged amino acids.
The initial agent of the TXCAs is Tranexamic Acid (TA), a synthetic lysine analog created to provide antifibrinolysis. However, our testing revealed that TA antagonizes not just lysine, but also arginine and histidine, the three positively charged amino acids. It is often recognized that electrostatic bonds between proteins are an essential part of many biological activities, but our findings led us to explore the significant effects of using an agent capable of antagonizing those bonds, with beneficial effects in a very broad range of medical issues, including inhibition of microbial infections, cancer, and other diseases. (For further information, see Our Technology.)
Through inspiration and years of research, we have uncovered these novel benefits of TA, and several significant applications are involved in or ready for clinical study. Although TA is generic in some forms, we have protected our position through extensive new patent filings on methods of use and compositions of synthetic lysine analogs, new analogs and derivatives, creation of novel methods of administration, and combinations with other compounds.
Because of TA’s direct and secondary benefits with respect to various diseases, its outstanding safety record, and its various mechanisms of action, it makes an excellent candidate to combine with other drugs, which is one of the successful trends of the pharmaceutical industry for a number of reasons.
TA’s multiple MOAs, its excellent safety record, our testing thus far, and the underlying science give the new forms of TA and the TXCAs a very high likelihood of success.
We invite discussions with licensees, acquirors, or financial partners regarding combinations as well as further development and commercialization of our technologies.